The Four Exclusivities Behind Every Pharma Mega-Deal
When a buyer writes a $74 billion check for a drugmaker, they are not paying for the molecule. They are […]
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Post-Approval Patents: The Hidden LOE Risk Map
Most pharmaceutical IP work gets framed as a pre-approval problem. File the composition patent during discovery, secure the use claims
Post-Approval Patents: The Hidden LOE Risk Map Read Post »
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens
The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Post-Approval Patent Strategy: How to Protect Your Drug from Regulatory and IP Risk After Approval
Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued
The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math
The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math Read Post »
The Patent Dance Decoded: How Biosimilar Developers Win or Lose Before Litigation Starts
The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps
The Patent Dance Decoded: How Biosimilar Developers Win or Lose Before Litigation Starts Read Post »
How NLP and AI Predict Drug Patent Expiration and Litigation Risk Before Your Competitors Do
The pharmaceutical industry has always run on information asymmetry. The company that knows, six months before its competitors, that a
